Traders Purchase High Volume of Pfizer Call Options (PFE)
Pfizer (NYSE:PFE) was the recipient of some unusual options trading activity on Friday. Investors acquired 43,511 call options on the company, Analyst Ratings.Net reports. This is an increase of approximately 201% compared to the typical daily volume of 14,447 call options.
A number of research firms have recently commented on PFE. Analysts at Jefferies Group reiterated a “hold” rating on shares of Pfizer in a research note to investors on Friday, October 11th. Separately, analysts at Credit Suisse initiated coverage on shares of Pfizer in a research note to investors on Tuesday, October 8th. They set an “outperform” rating and a $34.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. raised their price target on shares of Pfizer from $33.00 to $34.00 in a research note to investors on Friday, September 27th. They now have an “overweight” rating on the stock. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $30.92.
Pfizer (NYSE:PFE) opened at 30.51 on Monday. Pfizer has a one year low of $23.55 and a one year high of $31.15. The stock has a 50-day moving average of $28.70 and a 200-day moving average of $28.77. The company has a market cap of $202.0 billion and a P/E ratio of 8.47.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The company reported $0.56 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.55 by $0.01. The company had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $13.02 billion. During the same quarter in the prior year, the company posted $0.62 earnings per share. The company’s quarterly revenue was down 7.1% on a year-over-year basis.
Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.